- Oral presentation
- Open access
- Published:
Clinical effectiveness of mupirocin for preventing S. aureus infections in non-surgical settings: a meta-analysis
Antimicrobial Resistance and Infection Control volume 4, Article number: O5 (2015)
Introduction
A protective effect of mupirocin has been seen among surgical, nonsurgical and dialysis patients. Our aim is to summarize evidence for mupirocin decolonization for prevention of S. aureus infections in non-surgical healthcare settings.
Objectives
To identify the optimal setting and patient population to implement mupirocin decolonization for prevention of S. aureus infections using meta-analytic methods.
Methods
We conducted systematic searches in PubMed, Cochrane Library Databases, Scopus, Web of Science, and ClinicalTrials.gov to identify papers published until 2013 on effectiveness of mupirocin in healthcare settings. Two investigators independently abstracted data with a pilot-tested form. Risk of bias was assessed using the Cochrane tool. The crude odds ratios were pooled (cpOR) using a random-effects model. Heterogeneity was evaluated using the Woolf’s test for homogeneity and I2 statistics.
Results
Of the 12,644 studies identified, 8 randomized controlled trials and 19 quasi-experimental studies met the study inclusion criteria. Mupirocin was observed to reduce the odds of S. aureus infections by 70% (cpOR=0.30, 95% CI 0.23, 0.39) and 60% (cpOR=0.40, 95% CI 0.27, 0.62) in both dialysis and non-dialysis settings, respectively. Nevertheless, there was highly significant (p=0.0009) and moderate heterogeneity (I2=46%) among studies. Studies were homogeneous (p>0.1) when stratified analyses were performed by specific clinical settings. Among the 6 studies that took place in adult intensive care units (ICUs), mupirocin decolonization was associated with a 56% reduction in the odds of S. aureus infection (cpOR=0.44, 95% CI 0.26, 0.73). There was also a protective effect of mupirocin against S. aureus exit site infections among patients undergoing peritoneal dialysis (cpOR=0.23, 95% CI 0.15, 0.36) and against bacteremia among hemodialysis patients (cpOR=0.15, 95%CI 0.06, 0.36).
Conclusion
Mupirocin decolonization is protective against S. aureus infections among both dialysis and adult ICU patient populations. Future studies should target other patient settings such as long-term care facilities.
Disclosure of interest
None declared.
Author information
Authors and Affiliations
Rights and permissions
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Nair, R., Perencevich, E., Blevins, A. et al. Clinical effectiveness of mupirocin for preventing S. aureus infections in non-surgical settings: a meta-analysis. Antimicrob Resist Infect Control 4 (Suppl 1), O5 (2015). https://doi.org/10.1186/2047-2994-4-S1-O5
Published:
DOI: https://doi.org/10.1186/2047-2994-4-S1-O5